These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 2840751)

  • 1. DN.9693, a phosphodiesterase inhibitor, compared with prostaglandin E1 and prostacyclin in four platelet "function" tests.
    O'Brien JR; Etherington MD; Salmon GP
    Thromb Res; 1988 Apr; 50(1):237-41. PubMed ID: 2840751
    [No Abstract]   [Full Text] [Related]  

  • 2. DN 9693: a phosphodiesterase inhibitor with a platelet membrane effect.
    Jackson C; Ball J; Peel J; Lawry J; Greaves M; Preston FE
    Thromb Haemost; 1989 Apr; 61(2):266-9. PubMed ID: 2546286
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phosphodiesterase inhibitors as antiplatelet agents in vascular surgery.
    Kambayashi J; Watase M; Kawasaki T; Shiba E; Sakon M; Mori T; Isaka Y; Kimura K; Kamada T
    Adv Second Messenger Phosphoprotein Res; 1992; 25():383-93. PubMed ID: 1313269
    [No Abstract]   [Full Text] [Related]  

  • 4. Demonstration of functional compartments of cyclic AMP in rat platelets by the use of phosphodiesterase inhibitors.
    Ashida S; Sakuma K
    Adv Second Messenger Phosphoprotein Res; 1992; 25():229-39. PubMed ID: 1313259
    [No Abstract]   [Full Text] [Related]  

  • 5. Interactions between prostaglandin E2 and inhibitors of platelet aggregation which act through cyclic AMP.
    Gray SJ; Heptinstall S
    Eur J Pharmacol; 1991 Feb; 194(1):63-70. PubMed ID: 1647965
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 7-Bromo-1,5-dihydro-3,6-dimethylimidazo[2,1-b]quinazolin-2(3H)- one (Ro 15-2041), a potent antithrombotic agent that selectively inhibits platelet cyclic AMP-phosphodiesterase.
    Muggli R; Tschopp TB; Mittelholzer E; Baumgartner HR
    J Pharmacol Exp Ther; 1985 Oct; 235(1):212-9. PubMed ID: 2995647
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anagrelide: a potent and selective inhibitor of platelet cyclic AMP phosphodiesterase enzyme activity.
    Gillespie E
    Biochem Pharmacol; 1988 Jul; 37(14):2866-8. PubMed ID: 2456068
    [No Abstract]   [Full Text] [Related]  

  • 8. A new insight of anti-platelet effects of sirtinol in platelets aggregation via cyclic AMP phosphodiesterase.
    Liu FC; Liao CH; Chang YW; Liou JT; Day YJ
    Biochem Pharmacol; 2009 Apr; 77(8):1364-73. PubMed ID: 19426675
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of DN-9693, a new metastasis inhibitor, on murine hematogenous metastasis.
    Tanaka NG; Tohgo A; Ogawa H; Osada Y
    Anticancer Res; 1986; 6(4):543-8. PubMed ID: 3019218
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibitory effects of DN-9693 on platelet-enhanced tumor cell attachment to cultured endothelium.
    Tohgo A; Tanaka NG; Osada Y
    Invasion Metastasis; 1990; 10(1):1-17. PubMed ID: 2154413
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical application of a new in vitro bleeding time device on surgical patients.
    Tsujinaka T; Itoh T; Uemura Y; Sakon M; Kambayashi J; Mori T
    Jpn J Surg; 1988 Jul; 18(4):430-7. PubMed ID: 2845175
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of DN-9693, a selective inhibitor of cyclic AMP phosphodiesterase, in isolated and perfused canine large coronary arteries.
    Nakane T; Chiba S
    Jpn J Pharmacol; 1988 Dec; 48(4):507-9. PubMed ID: 2468805
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HL 725, an extremely potent inhibitor of platelet phosphodiesterase and induced platelet aggregation in vitro.
    Ruppert D; Weithmann KU
    Life Sci; 1982 Nov; 31(19):2037-43. PubMed ID: 6294426
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of TRK-100, a stable prostacyclin analogue, on regulation of cyclic AMP metabolism in platelets.
    Nogimori K; Kajikawa N; Nishio S; Yajima M
    Prostaglandins; 1989 Feb; 37(2):205-12. PubMed ID: 2543034
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacology of a potent, new antithrombotic agent, 1,3-dihydro-7,8-dimethyl-2H-imidazo[4,5-b]quinolin-2-one (BMY-20844).
    Buchanan JO; Fleming JS; Cornish BT; Baryla UM; Gillespie E; Stanton HC; Seiler SM; Keely SL
    Thromb Res; 1989 Nov; 56(3):333-46. PubMed ID: 2559492
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potentiation of anti-platelet aggregating activity of cilostazol with vascular endothelial cells.
    Igawa T; Tani T; Chijiwa T; Shiragiku T; Shimidzu S; Kawamura K; Kato S; Unemi F; Kimura Y
    Thromb Res; 1990 Feb; 57(4):617-23. PubMed ID: 2158154
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potent effects of novel anti-platelet aggregatory cilostamide analogues on recombinant cyclic nucleotide phosphodiesterase isozyme activity.
    Sudo T; Tachibana K; Toga K; Tochizawa S; Inoue Y; Kimura Y; Hidaka H
    Biochem Pharmacol; 2000 Feb; 59(4):347-56. PubMed ID: 10644042
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Decrease of platelet aggregation and spreading via inhibition of the cAMP phosphodiesterase by trapidil.
    Mazurov AV; Menshikov MYu ; Leytin VL; Tkachuk VA; Repin VS
    FEBS Lett; 1984 Jul; 172(2):167-71. PubMed ID: 6086387
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanisms of antiplatelet activity of PC-09, a newly synthesized pyridazinone derivative.
    Cherng SC; Huang WH; Shiau CY; Lee AR; Chou TC
    Eur J Pharmacol; 2006 Feb; 532(1-2):32-7. PubMed ID: 16457809
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevention of coronary platelet aggregation with a phosphodiesterase inhibitor RX-RA 69.
    Machleidt C; Rose P; Mittmann U
    Thromb Res; 1985 Mar; 37(5):595-604. PubMed ID: 2984803
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.